Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent advances in enterotoxin vaccine adjuvants.
Crothers JW, Norton EB. Crothers JW, et al. Among authors: norton eb. Curr Opin Immunol. 2023 Dec;85:102398. doi: 10.1016/j.coi.2023.102398. Epub 2023 Nov 16. Curr Opin Immunol. 2023. PMID: 37976963 Free article. Review.
Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
Crothers JW, Ross Colgate E, Cowan KJ, Dickson DM, Walsh M, Carmolli M, Wright PF, Norton EB, Kirkpatrick BD. Crothers JW, et al. Among authors: norton eb. Vaccine. 2022 Apr 26;40(19):2705-2713. doi: 10.1016/j.vaccine.2022.03.056. Epub 2022 Mar 30. Vaccine. 2022. PMID: 35367069 Free PMC article. Clinical Trial.
Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705-2713].
Crothers JW, Ross Colgate E, Cowan KJ, Dickson DM, Walsh M, Carmolli M, Wright PF, Norton EB, Kirkpatrick BD. Crothers JW, et al. Among authors: norton eb. Vaccine. 2022 May 31;40(25):3481. doi: 10.1016/j.vaccine.2022.05.001. Epub 2022 May 6. Vaccine. 2022. PMID: 35534312 Free PMC article. No abstract available.
Vaccine-elicited IL-1R signaling results in Th17 TRM-mediated immunity.
Hoffmann JP, Srivastava A, Yang H, Iwanaga N, Remcho TP, Hewes JL, Sharoff R, Song K, Norton EB, Kolls JK, McCombs JE. Hoffmann JP, et al. Among authors: norton eb. Commun Biol. 2024 Apr 9;7(1):433. doi: 10.1038/s42003-024-06138-0. Commun Biol. 2024. PMID: 38594380 Free PMC article.
The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.
Clements JD, Norton EB. Clements JD, et al. Among authors: norton eb. mSphere. 2018 Jul 25;3(4):e00215-18. doi: 10.1128/mSphere.00215-18. mSphere. 2018. PMID: 30045966 Free PMC article. Review.
Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
Maciel M Jr, Bauer D, Baudier RL, Bitoun J, Clements JD, Poole ST, Smith MA, Kaminski RW, Savarino SJ, Norton EB. Maciel M Jr, et al. Among authors: norton eb. Infect Immun. 2019 Oct 18;87(11):e00460-19. doi: 10.1128/IAI.00460-19. Print 2019 Nov. Infect Immun. 2019. PMID: 31427449 Free PMC article.
50 results